Compare Viatris Inc (VTRS) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Xpeng Inc - ADR — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Xpeng Inc - ADR trades at $13.38 (market cap $12.96B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.83% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| VTRS | XPEV | |
|---|---|---|
Market Cap | $19.79B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.39 | $28.07 |
52-Week Low | $8.74 | $12.09 |
Enterprise Value | $32.00B | $15.07B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XPeng (XPEV) trades at $13.33, down 1.52% today, with a bearish technical signal and neutral oscillators. Revenue grew to $76.72B in 2025, but net income remained negative at -$1.14B, with improving margins. Recent news highlights global expansion, including the L03 SUV launch in Munich and Robotaxi testing, while Q2 2026 deliveries of 103,295 vehicles beat expectations, signaling demand recovery.
The stock offers upside to the $17.00 analyst target but faces risks from intense EV competition and persistent losses. Investor sentiment is mixed, with 64.7% of analysts rating it Buy, yet technical trends and cash flow volatility warrant caution. Key catalysts include new model launches and international growth, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
